Clinical Trials Directory

Trials / Completed

CompletedNCT00461617

Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients

Multicentre, Double-Dummy, Randomized, Double-Blind Comparison Between Mitiglinide and Nateglinide in the Patients With Type 2 Diabetes

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
291 (actual)
Sponsor
Kissei Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
25 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of Mitiglinide compared to Nateglinide for the treatment of type 2 diabetes.

Conditions

Interventions

TypeNameDescription
DRUGMitiglinide10mg tablet, 10mg TID

Timeline

Start date
2006-08-01
Primary completion
2007-07-01
Completion
2007-07-01
First posted
2007-04-18
Last updated
2008-10-21

Source: ClinicalTrials.gov record NCT00461617. Inclusion in this directory is not an endorsement.

Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients (NCT00461617) · Clinical Trials Directory